Clinical trial · no report yet · Phase 2
DEWI
DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study
- NCT06059495 ↗
- Recruiting
- GERCOR - Multidisciplinary Oncology Cooperative Group
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 6 |
The trial
ClinicalTrials.gov- Official title
- Watch-and-wait Strategy to Initiate Dostarlimab-based Immunotherapy in Localized Deficient Mismatch Repair (dMMR) and/or Microsatellite Instability High (MSI-H) oEso-gastric Junction and Gastric Adenocarcinoma: An Open-label GERCOR Phase II Study
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Adenocarcinoma - GEJ; Gastric Adenocarcinoma
- Interventions
- Dostarlimab
- Arms
- Dostarlimab-based treatment · Experimental
- Enrollment
- 89 (estimated)
- Primary outcomes
- Clinical complete response (cCR)
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
- Start
- Jan 22, 2024
- Primary completion
- Sep 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06059495 · updated Aug 26, 2026